Data from historic phase IIb clinical trial for tuberculosis vaccine candidate MVA85A

05-Feb-2013 - Data from a Phase IIb clinical trial evaluating the safety and efficacy of MVA85A in preventing tuberculosis (TB) in infants. MVA85A is a TB vaccine candidate designed to boost immune responses already primed by the Bacille Calmette-Guérin (BCG) vaccine, the currently licensed and widely used TB ...

Prokarium acquires key oral vaccine technology from Emergent BioSolutions

13-Jul-2012 - Prokarium Ltd, a spin-out company of Cobra Biologics, completed a key technology acquisition from Emergent BioSolutions Inc. The technology includes Emergent’s live Salmonella-based typhoid vaccine TyphellaTM and its genetic technology spi-VECTM. Prokarium will combine TyphellaTM and spi-VECTM ...

Emergent Biosolutions announces appointment of Jay Coupe to Board of Directors

02-Nov-2005 - Emergent BioSolutions Inc. announced appointment of Jay Coupe to its Board of Directors. Mr. Coupe is the president of Coupe Associates, an international public policy and marketing consulting firm with clients in the United States, Europe and Asia. He graduated from Princeton University with a ...

Emergent BioSolutions Announces Appointment of Ronald Richard to the Board of Directors

28-Jan-2005 - Emergent BioSolutions Inc. announced the appointment of Ronald Richard to join its six-person Board of Directors. Mr. Richard is currently the President and CEO of the Cleveland Foundation, the nation's oldest community foundation, which has more than $1.6 billion in assets. Mr. Richard has also ...

Emergent BioSolutions and HPA Announce Botulinum Vaccine Collaboration

Botulism Ranks in CDC's Category "A" Threat List for Bioweapons

18-Jan-2005 - Emergent BioSolutions and the British-based Health Protection Agency (HPA) announced a two-year collaboration for the development of vaccines to prevent botulism. These two leaders in biodefense vaccines have long-established capabilities in the prevention of botulism dating to the 1950s. In a ...